

### **LANXESS – FY and Q4 2019 Roadshow**

**Delivering in challenging environment** 

### Safe harbor statement



The information included in this presentation is being provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to purchase, securities of LANXESS AG. No public market exists for the securities of LANXESS AG in the United States.

This presentation contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.

# LANXESS is a globally operating chemical player with attractive growth in specialties



Leading and balanced business setup

- Leading positions in attractive mid-sized markets
- Higher stability and resilience by a balanced product portfolio and industry exposure
- Competitive technology and cost structure



Attractive platform for growth

- Strong balance sheet as basis for further growth
- Focus on organic and external growth in niche and prospering future markets




Creating value

- Rigorous strategic and operational resource allocation
- Generating cash and acting sustainably for a better future
- Differentiating by a performance driven corporate culture



### Our journey so far – delivered on promises





### The face of LANXESS has substantially changed





### Despite a challenging environment we are well on track to achieve our goals



**EBITDA** pre margin (group, Ø through the cycle)



on track

**EBITDA** margin volatility



2019 stable vs. previous year



Cash conversion

>60%




- Ongoing transformation of business portfolio into Specialty **Chemicals**
- Strengthen and develop leadership positions in attractive markets
- Increasing footprint in **growing** regions (N. America and Asia)
- Further **improving margin** level
- Sound cash generation
- Stable or increasing dividend


### LANXESS margin improved well into targeted corridor



### FY 2019 margin at 15%

#### [EBITDA pre margin]






<sup>\*</sup> Group, average through the cycle

### FY 2019: More balanced portfolio proves resilience






**PUBLIC** 

# Effective 2020: New reporting structure to reflect respective business models






**Discontinued operations** 

# Impact of Covid-19 currently expected to be between €50 m and €100 m in 2020





#### **Current view on Covid-19 financial implications**

- Q1: EBITDA pre impact of ~€20 m due to
  - Temporary local production shutdowns in China
  - Disruption of some value chains in China
  - Globally weakened customer demand
- Q2: Worsening of impact expected
- Q3 +Q4: Potential gradual relief
- Total impact on LANXESS
  - €50 m if situation improves significantly until summer
  - Up to €100 m in case of longer disturbance of global economy

<sup>\*</sup> All sites operate again since 24 Feb

### Rely<sup>+</sup>On Virkon effective against Coronavirus




#### **Characteristics**

- Tests prove effectiveness
- Application flexibility with broad spectrum efficacy on hard surfaces
- Desinfection in public spaces: Train stations, airport, hospitals etc.


### **Demand & capacity**


- Increased worldwide demand for Rely+On Virkon, especially China
- Production und logistics currently being optimized for additional volumes



# FY 2020 outlook: LANXESS operationally stable at previous year level but Covid-19 will burden







### **Current view on economy**

- Ongoing geopolitical and macroeconomic uncertainties
- Corona virus (Covid-19) impacting business environment and further limiting visibility – financial impact for full year hard to predict
- Auto: no recovery ahead

### **LANXESS FY 2020 EBITDA pre**

- LANXESS operationally on previous year level (ex Covid-19)
- Covid-19 will impact Q1 by ~€20 m,
   FY impact currently expected between €50-100 m
- Based on the above, our outlook for the year is at €900-1000 m (including Covid-19 impact)

# LANXESS launches new share buy-back program Volume up to €500 m



### Legal framework

 Buy-back of up to 10% of the share capital in accordance with the authorization granted by the stockholders' meeting on 23 May 2019

#### Rationale

Maximizing the benefit of our investors based on best value creation

#### Volume

 Volume up to €500 m (execution in two tranches of €250 m each)

#### **Duration**

- Start earliest on 12 March 2020
- Shares will be acquired within next 24 months
- Acquired shares shall be redeemed





# Well positioned in challenging environment

On track to deliver 2021 financial targets

**Strong platform for further value creation** 

**Growing profitability and sustainable resilience** 



# LANXESS Energizing Chemistry

### **Agenda**

1 Time to prove our strengths

2 Business and Financial details Q4 2019

3 Back-up



# The way forward – Providing direction from four perspectives






# The way forward – Providing direction from four perspectives








# LANXESS continuously improves its portfolio - six M&A transactions executed in last 6 months





Supported by operational self-help measures (cost management, growth capex, innovations)

# The way forward – Continuous Portfolio Management





### Strategy




# Perfect match: The characteristics of Consumer Protection Chemicals and our competences





### **Characteristics:**

- High entry barriers due to increasing regulation
- Strong expertise in Regulatory Affairs
- Data ownership\* essential for product registration
- Attractive secular growth, independent of industry cycles



### Our competences:

- Global set-up in Regulatory
   Affairs
- Regulatory competence:
   One of the largest global expert teams in the industry
- Unique portfolio in Animal Protection Chemicals
- One of the strongest water purification technologies

# LANXESS Consumer Protection: Our products follow strong application-driven trends





### **Food Safety**

~5% Sales CAGR\* (2013-2019)





### **Water Purification**







### **Biosecurity**







# MPP proves its strong "specialty" financial performance



70 - 80%

Cash conversion

22 - 25% EBITDA pre margin

**CAGR: ~10%** 

Sales <€500 m

6 M&A since 2010

**0%**Automotive


# The way forward – Fix underperforming businesses






# Rigorously addressing under-performing businesses across our portfolio






### Strong progress in solving the Chrome problem







### Next logical step taken: LANXESS sells chrome ore mine in South Africa






- Disposal of LANXESS' 74% stake in chrome ore mine in Rustenburg (South Africa) to Clover Alloys (SA) Pty. Ltd.
- Sales: ~€60 m


- Internal employees: ~500
- Expected one-time-costs: ~€30 m
- Closing: Most likely end of 2020 (due to regulatory steps)

### **Strategic** rationale

- Chrome business no longer fits to our strategic focus
- Better future development under leadership of Clover Alloys


### Transaction scope





# Improving Organometallics' performance to competitive peer level





<sup>&</sup>lt;sup>1</sup> LANXESS Electronic Materials, Pyeongtaek (Korea)

# The way forward – Innovation





### **Strategy**



What innovations are we working on?

## We focus on product, process and technology innovation





#### **Our philosophy**

- Result-oriented product innovation
- Process innovation with focus on energy & resource efficiency
- Technology innovation that will change chemical business models (esp. digitalization)



### **Global innovation platform**

- 33 application centers in 14 countries focusing on product innovation
- Dedicated task force teams continuously optimize production processes worldwide
- Centralized digital team to introduce new technologies and change business models




### **Strong alliances**

- More than 150 research cooperations with customers, universities and other research institutes worldwide
- Collaboration with leading AI specialists Citrine, Palantir, et al.

# Strategic realignment is supported by product, process and technology innovation



#### **Key Chemicals for Li-Ion batteries**



- Standard Lithium Cooperation
   Pilot project to extract battery grade lithium from bromine wells in El Dorado
- Electrolyte salt (LiPF<sub>6</sub>), Chems for Anode & Cathode
- Battery Housing (PA / PBT components)

#### Natural beverage preservatives


Selected example



- Key market: USA; FDA approval received in 2018, further market approvals in preparation
- First meaningful sales in 2020
- Full potential to be reached 2025-2030
   (accessible initial market (USA): €200 m €250 m)

# Cooperation with Standard Lithium could deliver upside in a promising market





#### JV characteristics\*

- 60-70% LANXESS ownership
- Exclusive access to technology in Smackover formation
- Absorption of El Dorado infrastructure cost

#### **Project rationale**

- Use existing site infrastructure
- Brines from bromine wells in El Dorado contain Lithium
- Lithium demand growing double digit
- Limited additional cost during piloting
- In case of successful pilot project: €100-400 m capex possible\*\*

# The way forward – Digitalizing the value chain





# Digitalizing the value chain: CheMondis Paving the way to the future of trading chemicals









**Project start in 2017:** 

LANXESS' chemical industry knowledge combined with external digital experts

Pioneering into digital trading platform for chemicals to get ready for digital future

First minimal viable product (MVP) created in 2018, preparation of fully separated industry platform

Largest and fastest growing B2B marketplace for industrial chemicals in the western world

Exceptional team of skilled and dedicated experts combining chemical, digital and technical know-how

Unique setup, backed by industry know-how and capital

# Digitalizing the value chain LANXESS to be digital leader in the chemical industry





From itemized elements ...

... towards a fully integrated digitalized value chain:

R&D


Sourcing

**Production** 

Logistics

**Marketing/Sales** 

General/ Administration



# The way forward – Providing direction from four perspectives





### Portfolio additions most likely in Specialty Additives and along with transformation of Performance Chemicals



	Organic growth / Capex	Likelihood for M&A	Characteristics for M&A
Advanced Intermediates			
Specialty Additives			Synergies in related businesses
Performance			Attractive secular growth
Performance Chemicals			High entry barriers due to increasing regulation
Engineering Materials			

### The way forward – Providing direction from four perspectives







### Cash Conversion target also on track – but at what price does it come?



We could deliver on our Cash Conversion target already today, but give priority to profitable growth






#### Capital allocation follows shareholder interests



#### Shareholder return is the driver for capital allocation



### LANXESS strengthens its All aromatic "Verbund" with additional synthetic menthol capacity



Clear long-term investment approach based on synergetic customer relationship







#### **Investment rationale:**

- Significant increase in demand for synthetic menthol
- Strong customer relation based on long-term contracts
- Downstream development of the aromatic "Verbund"



### Venture investment into Lithium with low risk and potentially high return



Opportunity in cooperation with Standard Lithium



~€100 – 400 m

**Investments** 



Planned start of construction

#### **Investment rationale:**

- Potential lucrative yield of battery grade lithium from LANXESS' "waste material" tail brine
- Strong growth of Lithium use based on rising demand for batteries



#### Looking ahead ... energized!



**Profitability** 

Moving our way towards even more stable and attractive margin levels

Resilience

Further balanced exposure to end markets and regions in the future

**Financials** 

Maintaining strong financials and balanced debt

Rating

Commitment to stay solid investment grade




### The way forward – Providing direction from four perspectives





### LANXESS goes climate neutral by 2040 – New long-term commitment






- Clearly defined measures to reduce today's emissions
- Compensate growth effects with efficiency
- Majority of projects with reasonable investment costs
- Sustainable management is seen as a competitive advantage
- Good for LANXESS, good for our customers, good for our planet!

### LANXESS ahead of regulation and far sighted in management of ETS certificates





- LANXESS actively reduced CO<sub>2</sub>e emissions in line with Emission Trading Scheme (ETS) reduction targets
- Cost effect from ETS is currently neutral
- We will continue to reduce CO<sub>2</sub>e emissions and remain ahead of ETS reduction targets

### The way forward – Strongest set of opportunities since spin-off





#### **Agenda**

1 Time to prove our strengths

2 Financial and business details Q4 2019

3 Back-up



### Q4 2019: All four segments with improved earnings compared to previous year





- Ongoing successful portfolio management
  - Acquisition of biocide business in Brazil
  - Divestment of chrome value chain
  - Divestment of underperforming parts of Organometallics
- Increased EBITDA pre driven by better earnings in all four segments
- Strongly improved operating cash flow



- Lower sales prices and volumes due to:
  - Price decline in many raw materials
  - Persistent auto and agro weakness
- Continued low visibility due to hesitant order behavior

### LANXESS Group: Enhanced EBITDA and margin as promised



All four segments with improvement in Q4 EBITDA pre

[€m]*	Q4/2018	Q4/2019	Δ	FY 2018	FY 2019	Δ
Sales	1,674	1,636	-2%	6,824	6,802	0%
EBITDA pre	175	197	13%	986	1,019	3%
Margin	10.5%	12.0%		14.4%	15.0%	
CAPEX	235	213	-9%	482	508	5%



- Slight sales decline mainly due to raw material driven price reductions mitigated by positive FX effect
- Improved EBITDA pre and margin from successful strategy implementation and supportive FX effect. €10 m synergies planned for 2020 already realized in 2019
- For the first time FY EBITDA margin at 15%

<sup>\*</sup> All figures excluding BU LEA, which is reported as discontinued operations




#### **Advanced Intermediates: Strong earnings**



### Increasing support from BU Saltigo

[€m]	Q4/2018	Q4/2019	Δ	YTD 2018	YTD 2019	Δ
Sales	562	553	-2%	2,207	2,249	2%
EBITDA pre	73	79	8%	359	389	8%
Margin	13.0%	14.3%		16.3%	17.3%	
CAPEX	63	66	5%	155	162	5%



- Slight sales decrease driven by price decline in BU AII due to raw material price pass-through
- Positive volumes in both BUs and FX development mitigate price decline in sales
- Substantial EBITDA pre and margin improvement in Q4 and FY based on stronger volumes in BU AII and ongoing recovery in BU Saltigo




### **Specialty Additives: Ongoing strong margin improvement**



# Polymer Additives compensate weak auto demand

[€m]	Q4/2018	Q4/2019	Δ	YTD 2018	YTD 2019	Δ
Sales	470	471	0%	1,980	1,965	-1%
EBITDA pre	78	84	8%	343	353	3%
Margin	16.6%	17.8%		17.3%	18.0%	
CAPEX	65	47	-28%	141	120	-15%



- Stable sales: Positive pricing and FX effect compensate lower volume
- Favorable pricing in flame retardants overcompensates raw material driven price decline in lubricants
- Volume decrease due to lower auto demand (mainly BU RCH) and termination of margin-dilutive tolling agreements (BU LAB)
- Flame retardants, FX and accelerated synergies contribute to improved EBITDA pre and margin



### Performance Chemicals: All BUs with improved earnings - BU LEA discontinued operations



# Biocides and water purification boost performance

[€m]*	Q4/2018	Q4/2019	Δ	YTD 2018	YTD 2019	Δ
Sales	231	242	5%	976	1,052	8%
EBITDA pre	20	29	45%	156	192	23%
Margin	8.7%	12.0%		16.0%	18.3%	
CAPEX	27	22	-19%	61	60	-2%



Total **+5**%

Q4 Sales vs. PY

- Rise in sales due to pricing, volume and FX
- Positive price effect driven by BU MPP and LPT
- Volume growth mainly in BU MPP and LPT, stabilization in BU IPG
- Significant EBITDA pre and margin improvement in all three BUs, mainly driven by increased volumes and price
- Despite strong improvement, Q4 seasonally weakest quarter

<sup>\*</sup> All numbers excluding BU LEA, which is reported as discontinued operations



### **Engineering Materials: Good performance in a very difficult environment**



# Volume decline overstated by trade deal

[€m]	Q4/2018	Q4/2019	Δ	YTD 2018	YTD 2019	Δ
Sales	391	350	-10%	1,576	1,450	-8%
EBITDA pre	43	49	14%	267	238	-11%
Margin	11.0%	14.0%		16.9%	16.4%	
CAPEX	46	51	11%	76	104	37%



- Sales decrease on lower volumes and prices, slightly mitigated by FX
- Price decline in both BUs due to lower raw material prices
- Lower volumes in both BUs volume effect overstated by BU HPM trade deal in 2018. Demand from auto industry remains weak
- EBITDA pre and margin improvement in both BUs, comparing with a low Q4 2018

### Q4 2019: Good operational development partly offset by restructuring and M&A costs




[€m]	Q4/18		Q4/2019		yoy in %
Sales	1,674	(100%)	1,636	(100%)	-2%
Cost of sales	-1,309	(-78%)	-1,253	(-77%)	4%
Selling	-197	(-12%)	-203	(-12%)	-3%
G&A	-86	(-5%)	-81	(-5%)	6%
R&D	-27	(-2%)	-30	(-2%)	-11%
Others (incl. Except.)	-11	(-1%)	-69	(-4%)	>100%
EBIT	44	(3%)	0	(0%)	-100%
EPS pre*	0.77		0.64		-17%
EBITDA	162	(10%)	160	(10%)	-1%
thereof except.	-13	(-1%)	-37	(-2%)	<-100%
EBITDA pre except.	175	(10.5%)	197	(12.0%)	13%

- Improved costs of sales driven by lower raw material prices and volumes
- Decreased G&A costs mainly due to synergies
- EBIT impacted by higher exceptionals (restructuring, M&A, IT & digitization projects)

<sup>\*</sup> Net of exceptionals and amortization of intangible assets as well as attributable tax effects

#### Q4 2019: EBITDA pre increases in all segments






<sup>\*</sup> Total group sales including reconciliation

### Q4 2019: Further operational sales growth in Asia while Germany still suffers due to weak auto industry





<sup>\*</sup> Currency and portfolio adjusted

#### Strong increase in operating cash flow in Q4



[€m]	Q4/2018	Q4/2019	Δ
Operating cash flow*	172	267	95
Changes in working capital	102	212	110
Investing cash flow*	378	-270	-648
thereof capex	-235	-213	22

- Strong increase in operating cash flow mainly driven by improved working capital
- Investing cash flow in previous year biased by proceeds from ARLANXEO divestment
- Decrease in capex due to different timing of spending during fiscal year

<sup>\*</sup> applies to continuing operations

#### Balance sheet positions influenced by FX



[€m]	31.12.2018	31.12.2019
Total assets	8,687	8,695
Equity	2,773	2,647
Equity ratio	32%	30%
Net financial debt <sup>1</sup>	1,381	1,742
Pension provisions	1,083	1,178
Net working capital	1,455	1,308
DSI (in days) <sup>2</sup>	69	66
DSO (in days) <sup>3</sup>	46	42

- Decrease in equity mainly due to share buy-back and FX effect
- Net debt impacted by:
  - Share buy-back (€200 m)
  - IFRS 16 effect (~€130 m)
  - Dividend payment (€79 m)
- Increase in pension provisions arises from declining underlying interest rates in Germany, UK and the US
- Improved working capital caused by reduced inventories and trade receivables

<sup>&</sup>lt;sup>1</sup> Including cash, cash equivalents and near cash assets and after deduction of short-term money market investments

<sup>&</sup>lt;sup>2</sup> Days sales of inventory calculated from quarterly sales

<sup>&</sup>lt;sup>3</sup> Days of sales outstanding calculated from quarterly sales

#### **Agenda**

1 Time to prove our strengths

2 Financial and business details Q4 2019

3 Back-up



#### Housekeeping items 2020



**Capex 2020** 

Operational D&A 2020

Reconciliation 2020

Tax rate

Exceptionals 2020

FX sensitivity

Remnant costs

Maintenance shutdown BU HPM

~€500 m

~€450 m

~€160 m - €170 m including remnant costs

~28%

~€50 m based on current initiatives

One cent change of USD/EUR resulting in ~€7 m EBITDA pre impact before hedging

**~€10 m** p.a. until 2022

~**€10 - €20 m** in H2

### BU LEA accounted for as "Discontinued Operations" in 2019 – key P&L figures restated



Sales

2018					
[in €m]	LXS	Discontinued Operations	LXS Continued		
	<u>reported</u>	LEA	restated		
FY	7,197	373	6,824		
Q1					
Q2					
Q3					
Q4	1,766	92	1,674		

2019				
Discontinued Operations	LXS			
LEA	Continued			
329	6,802			
84	1,738			
86	1,724			
77	1,704			
82	1,636			

**EBITDA** pre

2018					
[in €m]	LXS	Discontinued Operations	LXS Continued		
[iii eiii]	reported	LEA	restated		
FY	1,016	30	986		
Q1					
Q2					
Q3					
Q4	179	4	175		

2019					
Discontinued Operations	LXS				
LEA	Continued				
0	1,019				
3	272				
5	281				
-2	269				
-6	197				

**EPS** pre

2018						
[in €m]	LXS Continued (Ex. ARL) reported	Discontinued Operations LEA	LXS Continued restated			
FY	4.45	-0.03	4.48			
Q1						
Q2						
Q3 Q4	0.61	-0.16	0.77			

2019					
Discontinued Operations	LXS				
LEA*	Continued				
-0.24	4.73				
-0.04	1.32				
0.03	1.48				
-0.08	1.29				
-0.16	0.64				

<sup>\*</sup> Figures do not fully add up as the average number of shares outstanding varies across the year due to cancellation of shares after the conducted the share buy-back

### Details on accounting for discontinued operations of BU Leather (starting FY 2019)



#### Income statement

- A discontinued operation is reported as income separate from continued operations
- EPS from discontinued, continuing & total to be reported
- Restatement of 2018 figures

#### **Balance sheet**

- Line items "assets and liabilities held for sale and discontinued operations" will be shown under "current assets" and "current liabilities" respectively
- No restatement of 2018 figures

#### **Cash flow Statement**


- Presentation of cash flows from discontinuing operations in one line item
- Restatement of 2018 figures

#### ROCE

ROCE adjusted for "discontinued operations"

#### Key Figures\*: Delivering as promised





<sup>\*</sup> Continuing operations (excluding BU LEA, which is reported as discontinued operation)

### FY 2019: Improved EBITDA pre and share buy-back drive further EPS pre increase




[€m]	FY 2018		FY 2019		yoy in %
Sales	6,824	(100%)	6,802	(100%)	0%
Cost of sales	-5,086	(-75%)	-5,043	(-74%)	1%
Selling	-759	(-11%)	-812	(-12%)	-7%
G&A	-295	(-4%)	-274	(-4%)	7%
R&D	-109	(-2%)	-114	(-2%)	-5%
Others (incl. Except.)	-84	(-1%)	-152	(-2%)	-81%
EBIT	491	(7%)	407	(6%)	-17%
EPS pre*	4.48		4.73		6%
EBITDA	906	(13%)	910	(13%)	0%
thereof except.	-80	(-1%)	-109	(-2%)	-36%
EBITDA pre except.	986	(14.4%)	1,019	(15.0%)	3%

- Increase in selling expenses due to higher freight costs and FX
- Improved G&A costs reflect synergies
- EBIT impacted by higher exceptionals (realignment of Organometallics and leather businesses)
- EPS pre increase supported by share buyback

<sup>\*</sup> Net of exceptionals and amortization of intangible assets as well as attributable tax effects

### FY 2019: Improving earnings in three out of four segments






<sup>\*</sup> Total group sales including reconciliation

### FY 2019: Solid growth in Asia and North America supported by FY tailwind





<sup>\*</sup> Currency and portfolio adjusted

### Cash flow FY 2019: Active working capital management drives improvement in operating cash flow



[€m]	FY 2018	FY 2019	Δ
Operating cash flow*	441	634	193
Changes in working capital	-179	68	247
Investing cash flow*	80	-697	-777
thereof capex	-482	-508	-26

- Increase in operating cash flow driven by improved working capital, reflecting reduction of inventories and receivables
- Investing cash flow in previous year biased by proceeds from ARLANXEO divestment
- Capex increase driven by attractive debottlenecking investments

<sup>\*</sup> Applies to continuing operations

### Increase in exceptional items (on EBIT) due to higher realignment and project costs




[€m]		Q4 2	2018	Q4 :	2019	FY	2018	FY	2019
		Excep.	Thereof D&A	Excep.	Thereof D&A	Excep.	Thereof D&A	Excep.	Thereof D&A
Advance Interme		0	0	48	35	0	0	48	35
Specialt Additive	•	-6	1	7	0	3	0	18	2
Perform Chemic		12	10	-3	0	12	10	2	0
Enginee Material		0	-1	0	0	1	0	0	0
Reconc	liation	17	0	23	3	74	0	82	4
Total		23	10	75	38	90	10	150	41

#### Maturity profile actively managed and well balanced



#### Liquidity and maturity profile as per December 2019




#### **Long-term financing secured**

- Diversified financing sources
  - Bonds & private placements
  - Syndicated credit facility
- Average interest rate of financial liabilities ~2%
- Next bond maturity in 2021
- All group financing executed without financial covenants

<sup>\*</sup> Hybrid bond with contractual maturity date in 2076 has a first optional call date in 2023.

### **Upcoming events 2020 - Proactive capital market communication**





#### **Contact details Investor Relations**





Oliver Stratmann Head of Treasury & Investor Relations

Tel.: +49-221 8885 9611 Fax.: +49-221 8885 5400 Mobile: +49-175 30 49611

Email: Oliver.Stratmann@lanxess.com



André Simon
Head of Investor Relations

Tel.: +49-221 8885 3494 Mobile: +49-175 30 23494 Email: Andre.Simon@lanxess.com



Laura Stankowski
Investor Relations Assistant

Tel.: +49-221 8885 3262 Fax.: +49-221 8885 4944

Email: Laura.Stankowski@lanxess.com



Katharina Forster
Institutional Investors / Analysts / AGM

Tel.: +49-221 8885 1035 Mobile: +49-151 7461 2789

Email: Katharina.Forster@lanxess.com



**Eva Frerker** 

Institutional Investors / Analysts

Tel.: +49-221 8885 5249 Mobile: +49 151 7461 2969 Email: Eva.Frerker@lanxess.com



Jens Ussler
Institutional Investors / Analysts

Tel.: +49-221 8885 7344 Mobile: +49 151 7461 2913 Email: Jens.Ussler@lanxess.com





#### **Abbreviations**





#### **Advanced Intermediates**

All Advanced Industrial Intermediates

**SGO** Saltigo



#### **Performance Chemicals**

**IPG** Inorganic Pigments

**MPP** Material Protection Products

LPT Liquid Purification Technologies



#### **Specialty Additives**

**LAB** Lubricant Additives Business

**PLA** Polymer Additives

**RCH** Rhein Chemie



#### **Engineering Materials**

**HPM** High Performance Materials

**URE** Urethane Systems

# LANXESS Energizing Chemistry